GENTAMICIN SULFATE

Post-LOE

gentamicin sulfate

Bausch + Lomb

ANDAOPHTHALMICSOLUTION/DROPS

Approved

May 1994

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

GENTAMICIN SULFATE (gentamicin sulfate) by Bausch + Lomb is clinical pharmacology microbiology gentamicin sulfate is active in vitro against many strains of the following microorganisms: staphylococcus aureus, staphylococcus epidermidis, streptococcus pyogenes, streptococcus pneumoniae, enterobacter aerogenes, escherichia coli, haemophilus influenzae, klebsiella pneumoniae, neisseria gonorrhoeae, pseudomonas aeruginosa, and serratia marcescens. Approved for the topical treatment of ocular bacterial infections including conjunctivitis, keratitis, keratoconjunctivitis and 16 more indications. First approved in 1994.

Drug data last refreshed 20h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Microbiology Gentamicin sulfate is active in vitro against many strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae,…

Indications (19)

the topical treatment of ocular bacterial infections including conjunctivitis keratitis

Worked on GENTAMICIN SULFATE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.